Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Devon Energy Corp (DVN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Devon Energy Corp — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $221.2 (market cap $29.60B), while Devon Energy Corp trades at $44.87 (market cap $49.94B). The key difference: Devon Energy Corp is the larger of the two by market cap, and Devon Energy Corp pays a 2.82% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | DVN | |
|---|---|---|
Market Cap | $29.60B | $49.94B |
Sector | Health | Energy |
52-Week High | $491.22 | $52.07 |
52-Week Low | $205.48 | $31.74 |
Enterprise Value | $27.56B | $60.68B |
Dividend Yield | — | 2.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
Devon Energy (DVN) trades at $44.9, down 1.01% today, with a bullish technical signal and strong Q2 2026 earnings beat. The company reported EPS of $1.57 versus $1.40 expected, driven by merger synergies and higher oil prices. Valuation remains attractive with a P/E of 9.87 and P/S of 1.62. Recent news highlights a 33% dividend increase and $1.25 billion debt repayment, reinforcing financial health.
The outlook is positive given robust free cash flow, debt reduction targets, and analyst consensus price target of $61.91 implying 38% upside. Key risks include oil price volatility and integration challenges from the Coterra merger. Institutional sentiment is strongly bullish with 71% buy ratings, supporting a favorable risk-reward profile for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Devon Energy Corp
Devon Energy, based in Oklahoma City, is one of the largest independent exploration and production companies in North America. The firm's asset base is spread throughout onshore North America and includes exposure to the Delaware, STACK, Eagle Ford, Powder River Basin, and Bakken plays. At year-end 2021, Devon's proved reserves totaled 1.6 billion barrels of oil equivalent, and net production that year was 572 thousand boe/d, of which oil and natural gas liquids made up 74% of production, with natural gas accounting for the remainder.
Read more on DVN →
